Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment

被引:57
作者
Jiang, Chunyang [1 ]
Meng, Lingxiang [2 ]
Yang, Bingjun [1 ]
Luo, Xin [3 ]
机构
[1] Tianjin Union Med Ctr, Dept Thorac Surg, 190 Jieyuan Rd, Tianjin 300121, Peoples R China
[2] Tianjin Union Med Ctr, Anorectal Surg Ctr, Dept Anorectal Surg, Tianjin, Peoples R China
[3] Second Affiliated Hosp, Gansu Med Coll, Hosp PingLiang City 2, Dept Radiotherapy, Pingliang, Peoples R China
关键词
Cancer; CRISPR; Cas9; gene editing; therapy; ONE-STEP GENERATION; CELL LUNG-CANCER; COLORECTAL-CANCER; DNA METHYLATION; IN-VITRO; ACQUIRED-RESISTANCE; CHECKPOINT BLOCKADE; DRUG-RESISTANCE; PROTEIN-KINASE; BREAST-CANCER;
D O I
10.1111/cge.13589
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
In recent years, gene editing, especially that using clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9, has made great progress in the field of gene function. Rapid development of gene editing techniques has contributed to their significance in the field of medicine. Because the CRISPR/Cas9 gene editing tool is not only powerful but also has features such as strong specificity and high efficiency, it can accurately and rapidly screen the whole genome, facilitating the administration of gene therapy for specific diseases. In the field of tumor research, CRISPR/Cas9 can be used to edit genomes to explore the mechanisms of tumor occurrence, development, and metastasis. In these years, this system has been increasingly applied in tumor treatment research. CRISPR/Cas9 can be used to treat tumors by repairing mutations or knocking out specific genes. To date, numerous preliminary studies have been conducted on tumor treatment in related fields. CRISPR/Cas9 holds great promise for gene-level tumor treatment. Personalized and targeted therapy based on CRISPR/Cas9 will possibly shape the development of tumor therapy in the future. In this study, we review the findings of CRISPR/Cas9 for tumor treatment research to provide references for related future studies on the pathogenesis and clinical treatment of tumors.
引用
收藏
页码:73 / 88
页数:16
相关论文
共 166 条
[1]   Target sequencing and CRISPR/Cas editing reveal simultaneous loss of UTX and UTY in urothelial bladder cancer [J].
Ahn, Jinwoo ;
Kim, Kwang Hyun ;
Park, Sanghui ;
Ahn, Young-Ho ;
Kim, Ha Young ;
Yoon, Hana ;
Lee, Ji Hyun ;
Bang, Duhee ;
Lee, Dong Hyeon .
ONCOTARGET, 2016, 7 (39) :63252-63260
[2]   Signatures of mutational processes in human cancer [J].
Alexandrov, Ludmil B. ;
Nik-Zainal, Serena ;
Wedge, David C. ;
Aparicio, Samuel A. J. R. ;
Behjati, Sam ;
Biankin, Andrew V. ;
Bignell, Graham R. ;
Bolli, Niccolo ;
Borg, Ake ;
Borresen-Dale, Anne-Lise ;
Boyault, Sandrine ;
Burkhardt, Birgit ;
Butler, Adam P. ;
Caldas, Carlos ;
Davies, Helen R. ;
Desmedt, Christine ;
Eils, Roland ;
Eyfjord, Jorunn Erla ;
Foekens, John A. ;
Greaves, Mel ;
Hosoda, Fumie ;
Hutter, Barbara ;
Ilicic, Tomislav ;
Imbeaud, Sandrine ;
Imielinsk, Marcin ;
Jaeger, Natalie ;
Jones, David T. W. ;
Jones, David ;
Knappskog, Stian ;
Kool, Marcel ;
Lakhani, Sunil R. ;
Lopez-Otin, Carlos ;
Martin, Sancha ;
Munshi, Nikhil C. ;
Nakamura, Hiromi ;
Northcott, Paul A. ;
Pajic, Marina ;
Papaemmanuil, Elli ;
Paradiso, Angelo ;
Pearson, John V. ;
Puente, Xose S. ;
Raine, Keiran ;
Ramakrishna, Manasa ;
Richardson, Andrea L. ;
Richter, Julia ;
Rosenstiel, Philip ;
Schlesner, Matthias ;
Schumacher, Ton N. ;
Span, Paul N. ;
Teague, Jon W. .
NATURE, 2013, 500 (7463) :415-+
[3]   Roles of acid-extruding ion transporters in regulation of breast cancer cell growth in a 3-dimensional microenvironment [J].
Andersen, Anne Poder ;
Flinck, Mette ;
Oernbo, Eva Kjer ;
Pedersen, Nis Borbye ;
Viuff, Birgitte Martine ;
Pedersen, Stine Falsig .
MOLECULAR CANCER, 2016, 15
[4]  
Anelli V, 2017, ELIFE, V6, DOI [10.7554/eLife.20728, 10.7554/eLife.20728.001]
[5]   The role of exosomes and miRNAs in drug-resistance of cancer cells [J].
Bach, Duc-Hiep ;
Hong, Ji-Young ;
Park, Hyen Joo ;
Lee, Sang Kook .
INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (02) :220-230
[6]   miRNA control of tumor cell invasion and metastasis [J].
Baranwal, Somesh ;
Alahari, Suresh K. .
INTERNATIONAL JOURNAL OF CANCER, 2010, 126 (06) :1283-1290
[7]   Long noncoding RNAs and sulforaphane: a target for chemoprevention and suppression of prostate cancer [J].
Beaver, Laura M. ;
Kuintzle, Rachael ;
Buchanan, Alex ;
Wiley, Michelle W. ;
Glasser, Sarah T. ;
Wong, Carmen P. ;
Johnson, Gavin S. ;
Chang, Jeff H. ;
Lohr, Christiane V. ;
Williams, David E. ;
Dashwood, Roderick H. ;
Hendrix, David A. ;
Ho, Emily .
JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2017, 42 :72-83
[8]  
Belinsky SA, 2003, CANCER RES, V63, P7089
[9]   Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma [J].
Benamar, Mouadh ;
Guessous, Fadila ;
Du, Kangping ;
Corbett, Patrick ;
Obeid, Joseph ;
Gioeli, Daniel ;
Slingluff, Craig L., Jr. ;
Abbas, Tarek .
EBIOMEDICINE, 2016, 10 :85-100
[10]   Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells [J].
Bhatt, Michelle ;
Ivan, Cristina ;
Xie, Xiaolei ;
Siddik, Zahid H. .
ONCOTARGET, 2017, 8 (07) :10905-10918